Palonosetron intravenous - Helsinn Healthcare

Drug Profile

Palonosetron intravenous - Helsinn Healthcare

Alternative Names: 2-QHBIQO; Aloxi Injection; Nuowei; ONICIT; Onicit; Palonosetron hydrochloride; Paloxi; RS-25259; RS-25259-197; RS-42358-197

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche Palo Alto LLC
  • Developer CJ HealthCare; Helsinn; Taiho Pharmaceutical
  • Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting

Most Recent Events

  • 28 Jun 2018 Helsinn obtained distributorship for intravenous palonosetron in USA
  • 26 Jun 2018 The US Supreme Court grants certiorari to review a Federal Circuit Panel decision for petition by Helsinn regarding patent claims covering intravenous palonosetron
  • 05 Jun 2018 CJ HealthCare Corporation completes a phase II trial in Chemotherapy induced nausea and vomiting (Prevention, Combination therapy) in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top